Abstract
Population studies have consistently demonstrated an inverse association between HDL-C and the risk of coronary heart disease. As a result, HDL-C is gaining increasing interest as a therapeutic target. In this article, we review the mechanism of action for the postulated antiatherogenic effect of HDL-C and how current and future therapies can exploit this beneficial activity. The clinical evidence supporting various interventions to raise HDL-C, from lifestyle modifications to established drugs (e.g., niacin and fibrates) is reviewed. Finally, we discuss new and promising approaches to enhance HDL-C.
Original language | English |
---|---|
Pages (from-to) | 181-208 |
Number of pages | 28 |
Journal | Clinical Lipidology |
Volume | 6 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2011 |
Keywords
- CETP inhibitor
- HDL
- HDL functionality
- LDL
- apoA-I
- atherosclerosis
- fibrates
- niacin
- phosphate
- phospholipids
- reverse cholesterol transport
- sphingosine-1
- triglycerides